3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
6
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
9
Temozolomide
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Cisplatin
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
Etoposide
4
sargramostim
3
Vincristine
3
Thiotepa
3
Melphalan
3
Automobiles
3
fludarabine
2
aldesleukin
2
Thalidomide
2
Surveys and Questionnaires
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Eflornithine
2
Donepezil
2
Carmustine
2
Biopsy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors, Primitive
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts